SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Syncom Formulations (India) informs about newspaper publication

05 Feb 2020 Evaluate

Pursuant to Regulation 30 read with Schedule III Part A(A) and in compliance of Regulation 47(1)(a) of SEBI (LODR) Regulations, 2015 regarding publishing of intimation of notice of 4/2019-20 Board Meeting of the company scheduled to be held on Friday, 14th February 2020 at 4.00 PM at the Corporate Office of the Company, Syncom Formulations (India) has informed about submission of the newspaper advertisement published on 05.02.2010 in Free Press Journal English Newspaper and Marathi (vernacular) Newspaper.

The above information is a part of company’s filings submitted to BSE.

Syncom Formulations Share Price

14.01 0.34 (2.49%)
09-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1938.85
Dr. Reddys Labs. 1269.80
Cipla 1441.70
Zydus Lifesciences 1159.85
Lupin 2502.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: